Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Irinotecan in Pediatric Solid Tumors
NCT03245450Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of eribulin in rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Ewing sarcoma and 1 more, sponsored by Eisai Co., Ltd. Primary endpoints: Recommended Phase 2 Dose and Objective Response Rate. Started Mar 2018; status: completed.
02
Drugs
eribulin
03
Conditions
rhabdomyosarcoma (RMS)non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)Ewing sarcomasolid tumor
Beyond the preview
Go deeper on NCT03245450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245450.